{"url_path":"/sec/anro/10-q/2026/item-2","section_key":"item-2","section_title":"Item 2 Unregistered Sales of Equity Securities and Use of Proceeds","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1999480/0001999480-26-000012-index.html","accession_number":"0001999480-26-000012","cik":"0001999480","ticker":"ANRO","issuer_name":"Alto Neuroscience, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1999480/0001999480-26-000012-index.html","primary_entity_key":"0001999480","primary_entity_name":"Alto Neuroscience, Inc."},"word_count":205,"has_tables":true,"body_markdown":"Item 2. Unregistered Sales of Equity Securities and Use of Proceeds\n\nUnregistered Sales of Equity Securities\n\nExcept for those unregistered securities previously disclosed in a current report on Form 8-K filed with the SEC during the period covered by this report, we have not sold any securities under the Securities Act of 1933, as amended, or the Securities Act.\n\nUse of Proceeds from Public Offering of Common Stock\n\nOn February 1, 2024, our Registration Statement on Form S-1, as amended (File No. 333-276495) relating to our IPO was declared effective. On February 6, 2024, we closed the IPO and 9,246,000 shares of our common stock were issued and sold at a public offering price of $16.00 per share, inclusive of the exercise in full by the underwriters of their option to purchase up to an additional 1,206,000 shares of common stock.\n\nThe aggregate net proceeds from the IPO, after underwriting discounts and commissions, and other offering expenses of $4.6 million, were $133.0 million. There has been no material change in the planned use of proceeds from our IPO as described in our prospectus filed pursuant to Rule 424(b)(4) under the Securities Act with the SEC on February 5, 2024.\n\nIssuer Purchases of Equity Securities\n\nNone"}